Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | PAM | P19021 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3191369 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104018 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7220949 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL560522 | 1.00 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104054 | 0.99 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL5227791 | 0.96 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL821391 | 0.96 | MEN1 (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL739576 | 0.92 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3204051 | 0.89 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL1261121 | 0.88 | MEN1 (0.39) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118059259-A | Protein degradation agent and preparation method and application thereof | 深圳先进技术研究院 | 2024-05-24 | — | — | CN | disclosed |
| CN-112673008-B | Hypoxanthine compounds | 橘生药品工业株式会社 | 2023-07-18 | — | — | CN | disclosed |
| CN-116438189-A | Acyl phosphine oxide photoinitiator and application thereof | 爱克发有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116390929-A | UV curable inkjet inks and inkjet printing methods | 爱克发有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-110072950-B | Solder resist ink jet ink for manufacturing printed circuit board | 爱克发-格法特公司 | 2022-02-11 | — | — | CN | disclosed |
| US-10947402-B2 | Solder mask inkjet inks for manufacturing printed circuit boards | AFGA-GEVAERT NV (BE) | 2021-03-16 | — | — | US | disclosed |
| CN-110072950-A | For manufacturing the solder mask ink jet of printed circuit board | 爱克发-格法特公司 | 2019-07-30 | — | — | CN | disclosed |
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-2358689-B9 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-5011846-A | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-30 | — | — | US | disclosed |
| US-4906755-A | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0330788-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0330824-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmias | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0329904-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329903-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329902-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of psychosis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329905-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329932-A2 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments | MERRELL PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0266730-A1 | Esters of hexadydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | MEN1 3750/4885MAPT 3713/4885KMT2A 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.